Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
134
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

486
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
486

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Prevalence of metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus in India: A systematic review and meta-analysis.

The Indian journal of medical research·2026
Same author

Comprehensive evaluation of secondary causes of hypertension: Integrated screening for obstructive sleep apnea and primary aldosteronism.

Sleep medicine·2026
Same author

Spurious Plasma Adrenocorticotropic Hormone Level in a Patient With Adrenal Cushing Syndrome.

Ochsner journal·2026
Same author

Optimising patient selection for adrenal vein sampling in primary aldosteronism: role of biochemical markers and scoring systems.

Endocrine·2026
Same author

Primary aldosteronism in premature coronary artery disease: A cross-sectional study from a tertiary center in India.

Indian heart journal·2026
Same author

Pattern and Persistence of Islet Autoantibodies and their Immunogenetic Association among Type 1 Diabetes Patients from North India.

Indian journal of pediatrics·2025
Same journal

Control of muscle mass and accretion.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Multiple endocrine neoplasia type 2: From molecular genetics to precision therapy.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Nutritional advice for patients with obesity and prediabetes.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Effects of prolonged physical training on skeletal muscle mass accrual throughout the life span.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Type 2 diabetes and obesity in South Asian patients with polyendocrine metabolic ovarian syndrome: The emerging role of metabolomics.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Stress and the interaction of the hypothalamic-pituitary-adrenal axis with other pituitary axes and its consequences on muscle mass.

Best practice & research. Clinical endocrinology & metabolism·2026
查看所有相关文章

相关实验视频

Updated: Jul 12, 2025

Delivery of Antibodies into the Brain Using Focused Scanning Ultrasound
07:34

Delivery of Antibodies into the Brain Using Focused Scanning Ultrasound

Published on: July 18, 2020

3.1K

布罗苏马布:目前的状况和未来的前景

Alpesh Goyal1, Nikhil Tandon1

  • 1Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, Convergence Block, Room no 7002, Seventh Floor, New Delhi 110029, India.

Best practice & research. Clinical endocrinology & metabolism
|October 20, 2023
PubMed
概括
此摘要是机器生成的。

布罗苏马布通过向多余的FGF23,改善酸盐水平和骨健康,有效地治疗低酸性狂犬病. 这种疗法为这种罕见疾病提供了一种超越传统治疗方法的新方法.

关键词:
这就是Burosumab.在FGF-23中.这就是TIOIO的意思.XLH XLH 在线观看低酸盐血症是什么意思骨质疏松症是一种骨质疏松症.拉基茨 (Rickets) 是一种精神疾病.

更多相关视频

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K

相关实验视频

Last Updated: Jul 12, 2025

Delivery of Antibodies into the Brain Using Focused Scanning Ultrasound
07:34

Delivery of Antibodies into the Brain Using Focused Scanning Ultrasound

Published on: July 18, 2020

3.1K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K

科学领域:

  • 内分泌学 在内分泌学.
  • 腎臟病學 (nephrology) 是一種醫學專業.
  • 骨生物学 骨生物学

背景情况:

  • 由于过多的FGF23而导致的低酸性狂风/骨质疏松症通常使用酸盐和维生素D来治疗,这些酸盐和维生素D可以治疗症状,但不能治疗根本原因.
  • 传统的治疗方法可能会导致诸如甲和甲状腺功能障碍症等并发症,并且经常患有患者不良坚持.
  • 纤维细胞生长因子23 (FGF23) 的升高扰乱了酸盐和维生素D的新陈代谢,导致了显著的骨异常.

研究的目的:

  • 评估针对FGF23的单克隆抗体布罗苏马布 (Burosumab) 的疗效和安全性,用于治疗低血性狂风病和骨质疏松症.
  • 评估Burosumab对酸盐平衡,骨愈合和患者整体结果的影响.
  • 为患有FGF23介导的低酸性狂犬病/骨质疏松症的患者提供替代治疗策略.

主要方法:

  • 一种单克隆抗体布罗苏马布 (Burosumab) 向并中和了多余的FGF23.
  • 进行了临床试验 (第二阶段和第三阶段),以评估布罗苏马布的安全性和有效性.
  • 对患者的结果进行了监测,包括酸盐水平和恶心病愈合.

主要成果:

  • 布罗苏马布在临床试验中表明了整体的安全性和有效性.
  • 用布罗苏马布治疗导致改善酸盐平衡.
  • 在接受Burosumab治疗的患者中观察到风和骨质疏松症的愈合.
  • 现在,布罗苏马布已获得FDA的批准,用于X链接的低度血症 (XLH) 和瘤诱导的骨质疏松症 (TIO).

结论:

  • 布罗苏马布为FGF23过量提供了向性治疗,解决低酸血性狂风/骨质疏松症的根本原因.
  • 目前的专家建议,Burosumab应用于严重病例或对常规治疗无反应的人.
  • 对布罗苏马布的长期数据和成本效益进行进一步的调查是有必要的.